Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc. is a healthcare company dedicated to the development and commercialization of gastrointestinal products. It is best known for its flagship product, linaclotide, which is used to treat adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. This medication is marketed as LINZESS in the United States and CONSTELLA in Canada and the European Union. Additionally, Ironwood is advancing other treatments, such as MD-7246, an oral pain reliever for abdominal pain associated with gastrointestinal diseases, and IW 3718, a formulation in Phase III clinical trials for gastroesophageal reflux disease. The company has established collaboration agreements with Allergan and AstraZeneca for the development of linaclotide in several regions, and a license agreement with Astellas Pharma for its use in Japan. Founded in 1998 and formerly known as Microbia, Inc., Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts.
VectivBio
Acquisition in 2023
VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.